CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Fundamental Analysis

USA • NYSE Arca • NYSEARCA:CANF • US13471N3008

4.16 USD
-0.09 (-2.12%)
At close: Feb 6, 2026
4.1 USD
-0.06 (-1.44%)
Pre-Market: 2/9/2026, 4:00:15 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

CANF gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. CANF scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CANF is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CANF has reported negative net income.
  • In the past year CANF has reported a negative cash flow from operations.
  • In the past 5 years CANF always reported negative net income.
  • CANF had a negative operating cash flow in each of the past 5 years.
CANF Yearly Net Income VS EBIT VS OCF VS FCFCANF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • CANF's Return On Assets of -102.07% is on the low side compared to the rest of the industry. CANF is outperformed by 75.53% of its industry peers.
  • CANF has a Return On Equity of -188.34%. This is in the lower half of the industry: CANF underperforms 66.54% of its industry peers.
Industry RankSector Rank
ROA -102.07%
ROE -188.34%
ROIC N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
CANF Yearly ROA, ROE, ROICCANF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CANF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CANF Yearly Profit, Operating, Gross MarginsCANF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CANF has more shares outstanding
  • CANF has less shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CANF Yearly Shares OutstandingCANF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
CANF Yearly Total Debt VS Total AssetsCANF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -32.98, we must say that CANF is in the distress zone and has some risk of bankruptcy.
  • CANF's Altman-Z score of -32.98 is on the low side compared to the rest of the industry. CANF is outperformed by 88.72% of its industry peers.
  • CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.98
ROIC/WACCN/A
WACC8.73%
CANF Yearly LT Debt VS Equity VS FCFCANF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

  • A Current Ratio of 3.60 indicates that CANF has no problem at all paying its short term obligations.
  • The Current ratio of CANF (3.60) is comparable to the rest of the industry.
  • A Quick Ratio of 3.60 indicates that CANF has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.60, CANF is in line with its industry, outperforming 45.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
CANF Yearly Current Assets VS Current LiabilitesCANF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • CANF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.36%, which is quite impressive.
  • Looking at the last year, CANF shows a decrease in Revenue. The Revenue has decreased by -9.29% in the last year.
  • Measured over the past years, CANF shows a very negative growth in Revenue. The Revenue has been decreasing by -19.81% on average per year.
EPS 1Y (TTM)39.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.22%
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%-36.08%

3.2 Future

  • Based on estimates for the next years, CANF will show a very strong growth in Earnings Per Share. The EPS will grow by 25.99% on average per year.
  • Based on estimates for the next years, CANF will show a very strong growth in Revenue. The Revenue will grow by 35.00% on average per year.
EPS Next Y13.95%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y35%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CANF Yearly Revenue VS EstimatesCANF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M
CANF Yearly EPS VS EstimatesCANF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2023 2024 2025 -5K -10K -15K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CANF. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CANF Price Earnings VS Forward Price EarningsCANF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CANF Per share dataCANF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CANF's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CANF does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CAN FITE BIOPHARMA LTD-ADR

NYSEARCA:CANF (2/6/2026, 8:21:12 PM)

Premarket: 4.1 -0.06 (-1.44%)

4.16

-0.09 (-2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28
Earnings (Next)04-12
Inst Owners2.01%
Inst Owner Change1.28%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap3.55M
Revenue(TTM)674.00K
Net Income(TTM)-7.88M
Analysts80
Price TargetN/A
Short Float %N/A
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-26.46%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)99.34%
EPS NY rev (3m)99.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.27
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 0.85
EV/EBITDA N/A
EPS(TTM)-14.47
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-9.79
FCFYN/A
OCF(TTM)-9.79
OCFYN/A
SpS0.79
BVpS4.9
TBVpS4.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -102.07%
ROE -188.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.9%
Cap/Sales 0.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -32.98
F-Score3
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)49.68%
Cap/Depr(5y)88.86%
Cap/Sales(3y)0.71%
Cap/Sales(5y)1.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.22%
EPS Next Y13.95%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%-36.08%
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y35%
Revenue Next 5YN/A
EBIT growth 1Y0.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.49%
OCF growth 3YN/A
OCF growth 5YN/A

CAN FITE BIOPHARMA LTD-ADR / CANF FAQ

Can you provide the ChartMill fundamental rating for CAN FITE BIOPHARMA LTD-ADR?

ChartMill assigns a fundamental rating of 3 / 10 to CANF.


What is the valuation status of CAN FITE BIOPHARMA LTD-ADR (CANF) stock?

ChartMill assigns a valuation rating of 1 / 10 to CAN FITE BIOPHARMA LTD-ADR (CANF). This can be considered as Overvalued.


Can you provide the profitability details for CAN FITE BIOPHARMA LTD-ADR?

CAN FITE BIOPHARMA LTD-ADR (CANF) has a profitability rating of 0 / 10.


Can you provide the financial health for CANF stock?

The financial health rating of CAN FITE BIOPHARMA LTD-ADR (CANF) is 6 / 10.